Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 6c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $141 thousand versus the consensus estimate of $61.6 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Barclays sees global expansion intact, warns against market complacency
• Asante Gold defers $50M in capex amid strategic review
• Rank One Computing (ROC) Reiterated at Buy by Benchmark Post ZTC Acquisition